Mode
Text Size
Log in / Sign up
N/A Completed N=2,278

A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin

Source: ClinicalTrials.gov NCT00892008 ↗
Enrolled (actual)
2,278
Serious AEs
0.3%
Results posted
Nov 2009
Primary outcomePrimary: Number and Severity of Adverse Events (All Causalities); Baseline to Final Visit (Week 4) — 1; 1; 3; 1 participants

Summary

This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study. This was an open label study and patients were enrolled once the decision to prescribe the medication was made by the Investigator.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number and Severity of Adverse Events (All Causalities); Baseline to Final Visit (Week 4)
1; 1; 3; 1; 1; 1 —
PRIMARY
Discontinuations Due to Adverse Events
1; 1; 5; 3; 2; 26 —
SECONDARY
Change From Baseline in Visual Analogue Scale (VAS) Score
3.5; 5.1 —
SECONDARY
VAS Pain Score at Baseline (BL) and Second Visit
22; 0; 0; 0; 3; 300 —
SECONDARY
VAS Pain Score at Baseline and Final Visit
12; 0; 0; 13; 272; 19 —
SECONDARY
Physician's Clinical Global Impression (CGI) of Treatment Satisfaction at the Second and Final Visits
209; 6; 2; 0; 0; 55 —
SECONDARY
Patient's Clinical Global Impression (CGI) of Treatment Satisfaction at the Second and Final Visits
201; 11; 1; 0; 0; 47 —
SECONDARY
Physician's Clinical Global Impression (CGI) of Efficacy at Second and Final Visit
217; 8; 1; 0; 0; 53 —
SECONDARY
Patient's Clinical Global Impression (CGI) of Efficacy at Second and Final Visit
206; 8; 0; 0; 0; 50 —
SECONDARY
Physician's Clinical Global Impression (CGI) on Tolerability at Second and Final Viist
237; 12; 0; 0; 0; 60 —
SECONDARY
Patient's Clinical Global Impression (CGI) of Tolerability at Second and Final Visit
213; 14; 0; 0; 0; 51 —

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18 years old and above diagnosed with neuropathic pain.

Exclusion Criteria

  • Patients that are pregnant and lactating; and patients with known hypersensitivity to pregabalin or its related components.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00892008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search